CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis.

1,544 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors (2012, background): “We previously demonstrated that blockade of CD47-mediated SIRPα signaling using targeted monoclonal antibodies (mAbs) induced the phagocytosis of leukemia, lymphoma, and bladder cancer cells by human and mouse macrophages (5, 16, 17, 26).”
Exosome Theranostics: Biology and Translational Medicine (2018, background): “Exosomes derived from normal fibroblast-like mesenchymal cells are positive for CD47, a widely expressed transmembrane protein that is well known to protect cells from phagocytosis [177], and have excellent retention in the circulation; in contrast, liposomes are rapidly eliminated from the circulat”
Rhythmic modulation of the hematopoietic niche through neutrophil clearance (2013, positive): “In agreement with this possibility, we find a small but consistent reduction in the surface levels of CD47 in the CD62LLO population (Figure S1F), which may favor phagocytosis of aged neutrophils (Jaiswal et al., 2009).”
Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm (2010, background): “In turn, tumor cells shape their interaction with macrophages by escaping phagocytosi”